<DOC>
	<DOCNO>NCT00003217</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist methotrexate cyclophosphamide treat child stage III stage IV non-Hodgkin 's lymphoma acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Stage III Stage IV Non-Hodgkin 's Lymphoma Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate feasibility toxicity dose intensification methotrexate cyclophosphamide patient stage III IV small , noncleaved cell non-Hodgkin 's lymphoma B cell acute lymphoblastic leukemia . II . Estimate response rate survival patient therapy . OUTLINE : This two-stage study . Patients receive cytarabine either continuous infusion ( first stage ) bolus injection ( second stage ) . Patients stratified disease ( stage III non-Hodgkin 's lymphoma ( NHL ) v stage IV NHL v stage B acute lymphoblastic leukemia ) . Therapy patient consist alternate course `` A '' `` B '' . Patients stage III disease receive 4 course chemotherapy ( ABAB ) stage IV disease B cell acute lymphoblastic leukemia receive 6 chemotherapy course ( ABABAB ) . Course A - Induction : Patients receive intrathecal methotrexate ( IT MTX ) intrathecal cytarabine ( IT Ara-C ) day 1 , 4 , 11 . Dexamethasone administer IV orally twice day day 1-5 . Cyclophosphamide IV administer every 12 hour day 1-3 . Doxorubicin IV administer 15 minute begin 12 hour begin 6th dose cyclophosphamide ( day 4 ) . At time , vincristine IV administer , repeat day 11 . Patients begin filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) subcutaneously IV 30 minute day 5 . Course B - Induction : The first 10 patient enrol receive cytarabine continuous infusion second 10 patient enrol receive cytarabine bolus IV . Patients begin treatment day 18 receive methotrexate IV 24 hour plus IT MTX hour 1 . Dexamethasone administer IV orally twice day day 1-5 . After complete 24 hour IV MTX infusion , patient begin cytarabine continuous infusion 48 hour bolus IV every 12 hour 4 dos . Patients receive G-CSF subcutaneously IV 30 minute begin day 22 . Patients assess remission status day 36 . Course A - Consolidation : Patients receive dexamethasone IV orally twice day day 1-5 . IT MTX IT Ara-C administer day 1 4 . Cyclophosphamide administered Induction , vincristine IV doxorubicin IV 15 minute 12 hour later . Vincristine repeat 1 week later . G-CSF administration begin day 5 . Course B - Consolidation : Therapy begin day 22 dexamethasone administer previously . Methotrexate infusion IT MTX administer Course B - Induction , cytarabine ( either continuous infusion bolus IV ) . G-CSF also administer previously . Patients follow monthly first 6 month , every 2 month next 6 month , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study within 16 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically proven small , noncleaved cell nonHodgkin 's lymphoma , Burkitt 's lymphoma , nonBurkitt 's lymphoma , B cell acute lymphoblastic leukemia ( BALL ) Stage III IV BALL must FAB L3 morphology register POG9400 PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : HIV antibody positive allow Not pregnant lactate PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Prior emergency steroid therapy may allow Radiotherapy : Prior emergency radiotherapy may allow Surgery : Prior surgery allow Other : No concurrent dexamethasone antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
</DOC>